Skip to main content

Table 1 Demographics and baseline characteristics

From: An open-label extension study to demonstrate long-term safety and efficacy of ABP 501 in patients with rheumatoid arthritis

Variable ABP 501/ABP 501 (N = 230) RP/ABP 501 (N = 237) Total* (N = 467)
Women, n (%) 188 (81.7) 191 (80.6) 379 (81.2)
Age, mean (SD), years 54.7 (11.71) 56.1 (11.40) 55.4 (11.56)
Ethnicity, n (%)
 Hispanic or Latino 27 (11.7) 19 (8.0) 46 (9.9)
 Not Hispanic or Latino 202 (87.8) 217 (91.6) 419 (89.7)
Race, n (%)
 White 218 (94.8) 224 (94.5) 442 (94.6)
 Black or African American 8 (3.5) 12 (5.1) 20 (4.3)
 Asian 3 (1.3) 0 (0.0) 3 (0.6)
 Other 1 (0.4) 1 (0.4) 2 (0.4)
Geographic region, n (%)
 Eastern Europe 153 (66.5) 156 (65.8) 309 (66.2)
 Western Europe 12 (5.2) 19 (8.0) 31 (6.6)
 North America 65 (28.3) 62 (26.2) 127 (27.2)
Duration of RA at baseline of Parent Study, mean (SD), (years) 9.13 (7.873) 9.46 (8.060) 9.30 (7.961)
Duration of RA category at baseline of the parent study, n (%)
 ≤ 5 years 90 (39.1) 79 (33.3) 169 (36.2)
 ≥ 5 years 140 (60.9) 158 (66.7) 298 (63.8)
Investigator Global Health Assessment at baseline of the OLE study, mean (SD) 2.5 (1.88) 2.6 (1.80) 2.6 (1.84)
DAS28-CRP at baseline of the OLE study, mean (SD) 3.40 (1.361) 3.32 (1.299) 3.36 (1.329)
Prior biologic use for RA, n (%) 60 (26.1) 69 (29.1) 129 (27.6)
  1. DAS28 Disease Activity Score 28, RA rheumatoid arthritis, RP reference product, SD standard deviation, ABP 501/ABP 501 patients who continued on ABP 501 from the parent study, RP/ABP 501 patients who transitioned from RP in the parent study to ABP 501 in the OLE study
  2. *Total = ABP 501/ABP 501 and adalimumab RP/ABP 501 combined because OLE is a single-arm study
  3. Total number of patients enrolled